¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Unspecified contact dermatitis, unspecified cause"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • extended-wear contact lens
    ¿¬¼ÓÂø¿ëÄÜÅÃÆ®·»Áî, ¿¬¼ÓÂø¿ëÁ¢ÃË·»Áî
  • heel contact
    µÚÃàµó±â
  • hard contact lens
    ÇϵåÄÜÅÃÆ®·»Áî, °æ¼ºÄÜÅÃÆ®·»Áî
  • hydrophilic contact lens
    Ä£¼öÄÜÅÃÆ®·»Áî
  • immediate contact
    Áï½ÃÁ¢ÃË
  • indirect contact
    °£Á¢Á¢ÃË
  • intercellular contact
    ¼¼Æ÷»çÀÌÁ¢ÃË, ¼¼Æ÷°£Á¢ÃË
  • intercellular contact layer
    ¼¼Æ÷»çÀÌÁ¢ÃËÃþ, ¼¼Æ÷°£Á¢ÃËÁõ
  • primary contact
    ÀÏÂ÷Á¢ÃË
  • proximal contact
    ÀÎÁ¢¸éÁ¢ÃË
  • soft contact lens
    ¼ÒÇÁÆ®ÄÜÅÃÆ®·»Áî, ¿¬¼ºÄÜÅÃÆ®·»Áî
  • scleral contact lens
    °ø¸·ÄÜÅÃÆ®·»Áî
  • artificial dermatitis
    ÀΰøÇǺο°
  • atopic dermatitis
    ¾ÆÅäÇÇÇǺο°
  • autoimmune progesterone dermatitis
    ÀÚ°¡¸é¿ªÇÁ·Î°Ô½ºÅ×·ÐÇǺο°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • indirect contact
    °£Á¢Á¢ÃË
  • intercellular contact
    ¼¼Æ÷»çÀÌÁ¢ÃËÃþ
  • primary contact
    ÀÏÂ÷Á¢ÃË
  • proximal contact
    ÀÎÁ¢
  • secondary contact
    ÀÌÂ÷Á¢ÃË
  • three point balancing contact
    »ïÁ¡Á¢Ã˱³ÇÕ
  • extended-wear contact lens
    ¿¬¼ÓÂø¿ëÄÜÅÃÆ®·»Áî, ¿¬¼ÓÂø¿ëÁ¢ÃË·»Áî
  • hard contact lens
    ÇϵåÄÜÅÃÆ®·»Áî
  • hydrophilic contact lens
    Ä£¼öÄÜÅÃÆ®·»Áî
  • intercellular contact layer
    ¼¼Æ÷°£Á¢ÃËÃþ
  • scleral contact lens
    °ø¸·ÄÜÅÃÆ®·»Áî
  • soft contact lens
    ¼ÒÇÁÆ®ÄÜÅÃÆ®·»Áî
  • therapeutic contact lens
    Ä¡·áÄÜÅÃÆ®·»Áî
  • toric contact lens
    ³­½Ã±³Á¤ÄÜÅÃÆ®·»Áî
  • actinic dermatitis
    ±¤¼±ÇǺο°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gold dermatitis
    ±Ý ÇǺο°
  • gonococcal dermatitis
    ÀÓ±Õ¼º ÇǺο°
  • grass dermatitis
    Ç® ÇǺο°
  • halo dermatitis
    Èı¤ÇǺο°
  • herbicide dermatitis
    Á¦ÃÊÁ¦ ÇǺο°
  • ichthyosiform dermatitis
    ¾î¸°¼±¾çÇǺο°
  • industrial dermatitis
    »ê¾÷ÇǺο°(òÅåöù«Ý±òðü´)
  • infantile dermatitis
    ¿µ¾ÆÇǺο°.
  • infantile dermatitis
    ¿µ¾ÆÇǺο°
  • infectious eczematoid dermatitis
    Àü¿°¼º ½ÀÁø¾ç ÇǺο°
  • persistent superficial dermatitis
    Áö¼Ó¼º Ç¥À缺 ÇǺο°
  • photocontact dermatitis
    ±¤Á¢ÃËÇǺο°
  • photosensitive dermatitis
    ±¤¼±°ú¹Î¼º ÇǺο°(ÎÃàÊΦÚÂàõ ù«Ý±æú)
  • pigmented cosmetic dermatitis
    »ö¼ÒÄ§Âø È­Àåǰ ÇǺο°
  • pigmented purpuric lichenoid dermatitis
    »ö¼Ò¼º Àڹݼº ż±¾ç ÇǺο°(¡­í¹ Úèàõ÷ÄàÈåÆù«Ý±æú)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • contact angle
    Á¢Ã˰¢(ïÈõºÊÇ).
  • contact area
    ´ê´ÂºÎºÐ
  • contact blepharitis
    Á¢ÃË´«²¨Ç®¿°Áõ, Á¢Ã˾Ȱ˿°
  • contact carrier
    Á¢Ã˺¸±ÕÀÚ(ÊÙËÓË»Ëö).
  • contact cheilitis
    Á¢ÃË(ïÈõº) ÀÔ¼ú¿°
  • contact comfort
    Á¢ÃËÀ§¾È(ïÈõºêÐäÌ)
  • contact compound scan
    Á¢ÃË º¹ÇÕ ½ºÄµ
  • contact compound scan
    Á¢ÃË º¹ÇÕ (ïÈõº ÜÜùê) ½ºÄµ
  • contact compound scanner
    Á¢ÃË º¹ÇÕ (ïÈõº ÜÜùê) ½ºÄ³³Ê
  • contact dermatoconjunctivitis
    Á¢ÃËÇǺΰḷ¿°
  • contact eczema
    Á¢Ã˽ÀÁø
  • contact hypersensitivity
    Á¢Ã˼º °ú¹Î¹ÝÀÀ
  • contact immunotherapy
    Á¢ÃË ¸é¿ª Ä¡·á
  • contact infection
    Á¢Ã˰¨¿°
  • contact inhibition
    Á¢ÃËÀúÁö
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
STANDOUT soft thresholding and depth cueing of unspecified techniques
URD unspecified respiratory disease; upper respiratory disease
COD   1) Choice Of Drug
  2) Cause Of Death
  3) Chemical O2 Demand;...
IDA   1) Imino-Diacetic Acid
  2) Iron Deficiency Anemia
   &nb...
CM California mastitis [test]; calmodulin; capreomycin; carboxymethyl; cardiac murmur; cardiac muscle; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CH Contact hypersensitivity
CHS Contact hypersensitivity
CS Contact sensitivity
NCT Non Contact Tonometer
SCL Soft contact lens
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • perioral dermatitis
    ±¸°­ ÁÖÀ§ÀÇ ÇǺο°
    ºñÁø±¸¿¡¼­ºÎÅÍ À̺ο¡ È«¹Ý, È«»ö ±¸ÁøÀÇ »êÀç³»Áö ÁýÁ·. ¸ð¼¼Ç÷°ü È®Àå, ³óÆ÷, Àμ³À» º¸°ÔµÇ´Â ÁúȯÀ̰í ÀÚ°¢ÀûÀ¸·Î´Â °­ÇÑ ÀÛ¿­°¨ÀÌ ÀÖ´Ù. ºÒ¼Ò ¹èÇÕÀÇ °­·ÂÇÑ ½ºÅ×·ÎÀ̵åÁ¦ÀÇ Àå±â ¿Ü¿ëÀÌ ¿øÀÎÀ¸·Î »ý°¢µÇ°í ÀÖÀ¸¸ç ÀÔ ºÎºÐ¿¡ ±¹ÇÑµÈ °ÍÀ¸·Î °£ÁÖÇØµµ ÁÁ´Ù. Ä¡·á´Â ¿Ü¿ëÀÇ ÁßÁö¿Í Åׯ®¶ó »çÀÌŬ¸°°è Ç×»ý ¹°ÁúÀÇ Àå±â ³»º¹À» ÇÑ´Ù.
  • ring dermatitis
    ¹ÝÁö ÇǺο°
  • salvarsan dermatitis
    »ì¹Ù¸£»ê ÇǺο°
  • schistosome dermatitis
    ÁÖÇ÷ÈíÃæ¼º ÇǺο°
  • solar dermatitis
    Àϱ¤ ÇǺο°
  • stasis dermatitis
    ¿ïÇ÷¼º ÇǺο°
  • wear and tear dermatitis
    ¹Ýº¹ ÀÚ±Ø ÇǺο°
  • allergic contact reaction
    ¾Ë·¯Áö¼º Á¢ÃË ¹ÝÀÀ
  • allergic-toxic contact stomatitis
    ¾Ë·¯Áö-µ¶¼º Á¢ÃË ±¸³»¿°
  • assisted mediotrusive contact
    ³»Ãø¹æ À¯µµ Á¢ÃË
  • balancing occlusal contact
    ±ÕÇü ±³ÇÕ Á¢ÃË
    ºÎÀûÀýÇÑ ¿ë¾î. nonworking occlusal contactÀ» º¸½Ã¿À.
  • centric occlusal contact
    Á᫐ ±³ÇÕ Á¢ÃË
  • contact angle
    Á¢ÃË °¢
    °íü Ç¥¸é»ó¿¡ ¿ë¾×ÀÇ ¹æ¿ïÀ» ¶³¾î¶ß¸± °æ¿ì, °íü ¸é°ú ¾×ÀÚÀ¯Ç¥¸éÀÌ ÀÌ·ç´Â °¢.
  • contact area
    Á¢Ã˺Î
  • contact cheilitis
    Á¢Ã˼º ±¸¼ø¿°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
contact induced spreading The response in which contact between two epithelial cells leads to a stabilised contact and the increased spreading of the cells so that the area covered is greater than that covered by the two cells in isolation.
(18 Nov 1997)
contact inhibition The inhibition of continued growth and division of a cell or colony due to physical contact with other cells or colonies. The stopping of continued growth when a certain density of cells has been reached.
The momentary stopping of all movement when a mobile cell runs into another cell.
(09 Oct 1997)
contact inhibition of growth See: density dependent inhibition.
(18 Nov 1997)
contact inhibition of movement Reaction in which the direction of motion of a cell is altered following collision with another cell. In heterologous contacts both cell may respond (mutual inhibition) or only one (nonreciprocal). Type I contact inhibition involves paralysis of the locomotory machinery, Type II is a consequence of adhesive preference for the substratum rather than the dorsal surface of the other cell.
(18 Nov 1997)
contact inhibition of phagocytosis Phenomenon described in sheets of kidney epithelial cells that, when confluent, lose their weak phagocytic activity, probably because of a failure of adhesion of particles to the dorsal surface in the absence of ruffles.
(18 Nov 1997)
contact lens A lens that fits over the cornea and sclera or cornea only; used to correct refractive errors.
(05 Mar 2000)
contact lenses Curved shells of glass or plastic applied directly over the globe or cornea to correct refractive errors.
(12 Dec 1998)
contact lenses, extended-wear Hydrophilic contact lenses worn for an extended period or permanently.
(12 Dec 1998)
contact lenses, hydrophilic Soft, supple contact lenses made of plastic polymers which interact readily with water molecules. Many types are available, including continuous and extended-wear versions, which are gas-permeable and easily sterilised.
(12 Dec 1998)
contact lens solutions Sterile solutions used to clean and disinfect contact lenses.
(12 Dec 1998)
contact point That part of the proximal surface of a tooth which touches the adjacent tooth mesially or distally.
Synonym: contact point, point of proximal contact.
(05 Mar 2000)
contact rate <epidemiology> The rate at which susceptibles meet infecteds. Usually measured as individuals per unit time.
(05 Dec 1998)
contact sensitivity Allergic response to contact with irritant, usually a hypersensitivity.
(18 Nov 1997)
contact sites A Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling.
(18 Nov 1997)
contact sites B Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • contact potential
    Á¢ÃË ÀüÀ§Â÷
  • contact print
    ¹ÐÂø ÀÎÈ­
  • contact process
    (Ȳ»êÁ¦Á¶ÀÇ)Á¢Ã˹ý 0
  • contact visit
    Á¢Ã˹湮(¼ö°¨ÀÚ¿Í ¹æ¹®ÀÚÀÇ ¾Ç¼ö.Æ÷¿ËµîÀÌ Çã¿ëµÊ)
  • eye contact
    ½Ã¼±ÀÌ ¸¶ÁÖħ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á